Literature DB >> 2410277

Decreased vigilance and neurotransmitter synthesis after discontinuation of dietary treatment for phenylketonuria in adolescents.

H C Lou, F Güttler, C Lykkelund, P Bruhn, A Niederwieser.   

Abstract

Four adolescent or young adult patients with phenylketonuria were examined before and after discontinuation of dietary treatment. Plasma and CSF phenylalanine concentrations increased about two-fold in three patients. In these patients the CSF concentration of the dopamine and serotonin metabolites homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) decreased markedly; 5-HIAA to extremely low values. The reaction time variability increased in these patients. In the fourth case plasma phenylalanine levels, CSF HVA and 5-HIAA levels, and reaction time variability were essentially unchanged. The relationship between reaction time variability and the CSF 5-HIAA level for all four patients could be presented as a linear function. However, a causal relationship is still unproven. These preliminary findings demonstrate that there may be hazards in the discontinuation of dietary treatment, even in adolescents or young adults, for neurotransmitter metabolism and mental function.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2410277     DOI: 10.1007/bf00491918

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  11 in total

1.  Continuous reaction time in patients with hepatic encephalopathy. A quantitative measure of changes in consciousness.

Authors:  P Elsass; S E Christensen; L Ranek; A Theilgaard; N Tygstrup
Journal:  Scand J Gastroenterol       Date:  1981-04       Impact factor: 2.423

2.  Selective brain dopamine depletion in developing rats: an experimental model of minimal brain dysfunction.

Authors:  B A Shaywitz; R D Yager; J H Klopper
Journal:  Science       Date:  1976-01-23       Impact factor: 47.728

3.  High-performance liquid chromatography with column switching for the analysis of biogenic amine metabolites and pterins.

Authors:  A Niederwieser; W Staudenmann; E Wetzel
Journal:  J Chromatogr       Date:  1984-05-04

4.  Phenylalanine as substrate and inhibitor of tyrosine hydroxylase.

Authors:  M Ikeda; M Levitt; S Udenfriend
Journal:  Arch Biochem Biophys       Date:  1967-05       Impact factor: 4.013

5.  Neurotransmitter defects and treatment of disorders of hyperphenylalaninemia.

Authors:  I J Butler; M E O'Flynn; W E Seifert; R R Howell
Journal:  J Pediatr       Date:  1981-05       Impact factor: 4.406

6.  Effect of stopping low-phenylalanine diet on intellectual progress of children with phenylketonuria.

Authors:  I Smith; M E Lobascher; J E Stevenson; O H Wolff; H Schmidt; S Grubel-Kaiser; H Bickel
Journal:  Br Med J       Date:  1978-09-09

Review 7.  Hyperphenylalaninemia: diagnosis and classification of the various types of phenylalanine hydroxylase deficiency in childhood.

Authors:  F Güttler
Journal:  Acta Paediatr Scand Suppl       Date:  1980

8.  The involvement of 5-hydroxytryptamine in the release of dendritic dopamine from slices of rat substantia nigra.

Authors:  J Williams; J A Davies
Journal:  J Pharm Pharmacol       Date:  1983-11       Impact factor: 3.765

9.  Age effect on dopamine and serotonin metabolite levels in cerebrospinal fluid.

Authors:  W E Seifert; J L Foxx; I J Butler
Journal:  Ann Neurol       Date:  1980-07       Impact factor: 10.422

10.  Inhibition by L-phenylalanine of tryptophan transport by synaptosomal plasma membrane vesicles: implications in the pathogenesis of phenylketonuria.

Authors:  E Herrero; M C Aragon; C Gimenez; F Valdivieso
Journal:  J Inherit Metab Dis       Date:  1983       Impact factor: 4.982

View more
  36 in total

1.  Tackling frontal lobe-related functions in PKU through functional brain imaging: a Stroop task in adult patients.

Authors:  Benedikt Sundermann; Bettina Pfleiderer; Harald E Möller; Wolfram Schwindt; Josef Weglage; Jöran Lepsien; Reinhold Feldmann
Journal:  J Inherit Metab Dis       Date:  2011-04-14       Impact factor: 4.982

2.  Neurotransmitter therapy and diet in malignant phenylketonuria.

Authors:  A Ponzone; O Guardamagna; S Ferraris; S Biasetti; G Bracco; A Niederwieser
Journal:  Eur J Pediatr       Date:  1987-01       Impact factor: 3.183

3.  The control of 5-hydroxytryptamine and dopamine synthesis in the brain: a theoretical approach.

Authors:  F A Hommes; J S Lee
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

4.  Reduced urinary serotonin excretion after intake of high doses of hypoxanthine.

Authors:  H Manzke; H Gustmann
Journal:  Eur J Pediatr       Date:  1989-01       Impact factor: 3.183

5.  Phenylketonuric patients decades after diet.

Authors:  R O Fisch; P N Chang; S Weisberg; P Guldberg; F Güttler; M Y Tsai
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

6.  Neurological deterioration in adult phenylketonuria.

Authors:  D Villasana; I J Butler; J C Williams; S M Roongta
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

Review 7.  Acute tryptophan depletion in humans: a review of theoretical, practical and ethical aspects.

Authors:  Simon N Young
Journal:  J Psychiatry Neurosci       Date:  2013-09       Impact factor: 6.186

8.  Developmental timing of exposure to elevated levels of phenylalanine is associated with ADHD symptom expression.

Authors:  Kevin M Antshel; Susan E Waisbren
Journal:  J Abnorm Child Psychol       Date:  2003-12

Review 9.  Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Authors:  Dominic J Gessler; Guangping Gao
Journal:  Methods Mol Biol       Date:  2016

10.  Maternal tyrosinaemia II: management and successful outcome.

Authors:  D E Francis; D M Kirby; G N Thompson
Journal:  Eur J Pediatr       Date:  1992-03       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.